{"title":"Relationship between a diagnosis of kidney failure and heart diseases in patients with hyperkalaemia.","authors":"Josep Darbà, Meritxell Ascanio, Ainoa Agüera","doi":"10.1080/13696998.2024.2427512","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study seeks to determine the association between kidney failure and heart diseases by examining how they influence the diagnosis of hyperkalaemia.</p><p><strong>Methods: </strong>We employ a fuzzy regression discontinuity design (RDD) by harnessing the inherent threshold in potassium levels, which serves as a diagnostic criterion for hyperkalaemia. Simultaneously, we utilize patient diagnosis data related to kidney failure and heart diseases. This approach allows us to evaluate the causal impact of both diagnoses on hyperkalaemia.</p><p><strong>Results: </strong>Significant overall increases in the risk of developing hyperkalaemia are evident subsequent to a diagnosis of kidney failure or heart disease. The study finds that the probability of receiving a kidney failure diagnosis increases by 11.2% regarding a cut-off of 6 mEq/L of potassium. In addition, there is an 6.8% likelihood of experiencing hyperkalaemia in the case of a prior diagnosis of hypertension, and an 8.8% probability in the case of a diagnosis of depression. The findings remain robust when considering alternative parametric and non-parametric specifications as well as placebo tests.</p><p><strong>Conclusions: </strong>This study provides new empirical insights into the causal impact of kidney failure and heart disease, underscoring the significance of monitoring such patients to prevent serious complications in the future.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2024.2427512","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study seeks to determine the association between kidney failure and heart diseases by examining how they influence the diagnosis of hyperkalaemia.
Methods: We employ a fuzzy regression discontinuity design (RDD) by harnessing the inherent threshold in potassium levels, which serves as a diagnostic criterion for hyperkalaemia. Simultaneously, we utilize patient diagnosis data related to kidney failure and heart diseases. This approach allows us to evaluate the causal impact of both diagnoses on hyperkalaemia.
Results: Significant overall increases in the risk of developing hyperkalaemia are evident subsequent to a diagnosis of kidney failure or heart disease. The study finds that the probability of receiving a kidney failure diagnosis increases by 11.2% regarding a cut-off of 6 mEq/L of potassium. In addition, there is an 6.8% likelihood of experiencing hyperkalaemia in the case of a prior diagnosis of hypertension, and an 8.8% probability in the case of a diagnosis of depression. The findings remain robust when considering alternative parametric and non-parametric specifications as well as placebo tests.
Conclusions: This study provides new empirical insights into the causal impact of kidney failure and heart disease, underscoring the significance of monitoring such patients to prevent serious complications in the future.
期刊介绍:
Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication.
Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience